Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 103 (1), 19-27

Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Affiliations

Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Julie A Bradley et al. Int J Radiat Oncol Biol Phys.

Abstract

Purpose: For infants with localized rhabdomyosarcoma who were enrolled on Children's Oncology Group ARST0331 and ARST0531, local therapy guidelines were provided, but adherence was not mandated because of toxicity concerns. We examined adherence to protocol for local therapy guidelines, treatment variations, and outcomes for these patients.

Methods: Children aged ≤24 months who were enrolled on ARST0331 and ARST0531 were evaluated. Data were verified through radiologic, surgical, pathologic, and clinical records. Local therapy was assessed for adherence to protocol guidelines, with variations termed "individualized local therapy." The subdistribution hazards model assessed local failure, the Kaplan-Meier product limit method assessed event-free survival (EFS) and overall survival, and the log-rank test was used to evaluate prognostic impact.

Results: The median age of the patients was 14 months, and 124 patients were eligible. Common primary sites were genitourinary (40%), parameningeal (14%), and the extremities (11%). Most patients had unresected disease (group 3, 64%) and embryonal histology (73%). Fifty-eight percent of patients received radiation therapy at a median of week 12 (weeks 1-45). The median radiation dose was 48.6 Gy (30.6-54 Gy). Forty-three percent of patients received individualized local therapy (outside protocol guidelines), typically omission or delay of radiation therapy. Delayed primary excision was performed in 28% at a median of week 14 (weeks 7-34). With a median follow-up of 5.6 years, the 5-year local failure, EFS, and overall survival rates were 24%, 68%, and 82%, respectively. Local failure was significantly higher (35%) in patients receiving individualized local therapy than in patients who received protocol-specified local therapy (16%; P = .02). The site of failure was local in 64% of patients, local and distant in 5%, and distant only in 23%. EFS was significantly higher among patients who were aged 12 to 24 months, had tumors ≤5 cm, had group 1/2 disease, and underwent protocol-specified therapy.

Conclusions: Local recurrence was the predominant pattern of failure and was more common in those receiving individualized local therapy. De-escalation of effective therapies because of concerns about treatment toxicity should be considered cautiously.

Conflict of interest statement

Conflict of interest: Julie Bradley: travel grant from Ion Beam Applications for educational program

Figures

Figure 1.
Figure 1.
Local therapy for group II and III infants on ARST0331 and ARST0531 protocols consisted of radiation alone, surgery alone, surgery and radiation, and omission of local therapy
Figure 2.
Figure 2.
t Types of individualized local therapy for infants treated on ARST0331 and ARST0531. Some patients had multiple factors contributing to individualized local therapy.
Figure 3.
Figure 3.
(A) Event-free survival and (B) overall survival for infants on ARST0331 and ARST0531, older children on ARST0331 and ARST0531, and infants on D9602 and D9803
Figure 3.
Figure 3.
(A) Event-free survival and (B) overall survival for infants on ARST0331 and ARST0531, older children on ARST0331 and ARST0531, and infants on D9602 and D9803
Figure 4.
Figure 4.
Cumulative incidence of local failure for infants compared to older children treated on ARST0331 and ARST0531

Similar articles

See all similar articles

Cited by 1 article

Publication types

Feedback